Fatty acid-induced cholecystokinin secretion and changes in intracellular Ca2+ in two enteroendocrine cell lines, STC-1 and GLUTag.
1. Fatty acid-induced cholecystokinin (CCK) secretion in humans and from the enteroendocrine cell line STC-1 depends critically on acyl chain length. 2. Therefore we have characterized the relationship between acyl chain length and the potency of the fatty acid to induce CCK secretion and changes in intracellular Ca2+ concentration ([Ca2+]i) in two enteroendocrine cell lines (STC-1 and GLUTag). We found that the potency of the fatty acid was directly proportional to its chain length and therefore inversely proportional to its solubility. 3. In both cell types, the fatty acid-induced rise in [Ca2+]i in response to decanoic acid (C10), dodecanoic acid (C12) and tetradecanoic acid (C14) was significantly reduced in Ca2+-free medium and largely blocked by nicardipine. Intracellular stores also contributed to the overall shape of the [Ca2+]i peak. Thus all the fatty acids tested caused the release of Ca2+ from stores and influx of extracellular Ca2+, presumably through L-type calcium channels. 4. To probe the site of fatty acid action, we studied the distribution of 14C-labelled dodecanoic acid. This label was rapidly and irreversibly accumulated by both cell types, where it became concentrated about 20-fold. Confocal microscopy of a fluorescent analogue of dodecanoic acid clearly demonstrated that it entered the cytosol and was not merely partitioning in the cell membrane. These data indicate that an intracellular action for fatty acid-induced CCK secretion cannot be eliminated. 5. Dodecanoic acid itself, and not a metabolite, is the agent responsible for triggering Ca2+ entry since a non-metabolizable form of dodecanoic acid (2-bromododecanoic acid) was also capable of inducing a rise in [Ca2+]i in both cell types. 6. In conclusion, the rise in [Ca2+]i in STC-1 and GLUTag cells evoked by medium- to long-chain fatty acids results from the triggering of a specific signalling pathway. Whether triggering occurs through activation of a membrane-bound receptor or at an intracellular site remains to be clarified.
Sidhu
S S
SS
Schools of Biological Sciences and Medicine, The University of Manchester, Manchester M13 9PT, UK.
Thompson
D G
DG
Warhurst
G
G
Case
R M
RM
Benson
R S
RS
D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects; D002766:Cholecystokinin / Q000378:metabolism*; D003106:Colon / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D003652:Decanoic Acids / Q000378:metabolism / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D019858:Enteroendocrine Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005227:Fatty Acids / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007424:Intracellular Fluid / Q000378:metabolism*; D007850:Lauric Acids / Q000378:metabolism / Q000494:pharmacology; D015394:Molecular Structure; D019814:Myristic Acid / Q000378:metabolism / Q000494:pharmacology; D009529:Nicardipine / Q000494:pharmacology; D012710:Serum Albumin, Bovine / Q000494:pharmacology
D002121:Calcium Channel Blockers; D003652:Decanoic Acids; D005227:Fatty Acids; D007850:Lauric Acids; D019814:Myristic Acid; C065535:2-bromododecanoate; C030358:lauric acid; D012710:Serum Albumin, Bovine; C031071:decanoic acid; D002766:Cholecystokinin; D009529:Nicardipine; D002118:Calcium